Wilson's Disease in Significant Liver Fibrosis, Cirrhosis, or Liver Failure: What to Do When Chelation Therapy Fails

In patients with Wilson's disease who present with significant liver fibrosis, cirrhosis, liver failure, or haemolysis, chelation therapy is the primary treatment. When that first-line course does not produce the expected response, a defined next-line protocol applies.

Previous treatment & failure condition

First-line chelation therapy — D-penicillamine or trientine — was initiated for significant liver disease. Escalation to this protocol is warranted when jaundice and ascites remain unresolved, liver parameters (ALT, INR, albumin) have not sufficiently improved, and 24-hour urinary copper excretion has not reached the maintenance target range.

Next-line approach (partial overview)

The protocol centres on switching to an alternative chelating agent. The specific criteria, sequencing, and monitoring requirements are detailed in the full structured regimen…

Treatment targets

Resolution of jaundice and ascites
Improvement or normalisation of liver parameters (ALT, INR, albumin)
24-hour urinary copper excretion within the maintenance target range

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.jhep.2024.11.007

Chelators should be the primary choice in patients with significant liver disease, e.g. features of significant fibrosis and cirrhosis, liver failure, and haemolysis (LoE 3, strong recommendation, strong consensus).

In patients with WD who do not achieve sufficient treatment response on first-line therapy despite a good adherence to treatment and a 24-h urinary copper excretion in the target range, or side effects, switching treatment should be considered (D-penicillamine to trientine and vice versa or zinc to chelators) (LoE 2, strong recommendation, strong consensus).

View source ↗